December 2010 Blog Posts (58)

Smoking May Worsen Pain for Cancer Patients

Smoking is associated with increased pain severity and the extent to which pain interfered with a patient’s daily routine. While the relationship between smoking and cancer is well established, in a study led by a Texas A&M University professor, published in the January 2011 issue of PAIN, researcher for the first time report evidence to suggest that cancer patients who continue to smoke, despite their diagnosis, experience greater pain than nonsmokers.…

Continue

Added by Peter Hofland, PhD on December 23, 2010 at 1:00pm — No Comments

Nilotinib Approval Gives Patients With Newly Diagnosed Ph+ Chronic Myeloid Leukemia New Medical Option

The European Commission has approved nilotinib (Tasigna®, Novartis) as a treatment for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase.



Nilotinib is indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia (CML) in the chronic…

Continue

Added by Peter Hofland, PhD on December 23, 2010 at 12:30pm — No Comments

US Approves Merck's Gardasil to Prevent Anal Cancer

The U.S. Food and Drug Administration (FDA) today approved the vaccine Gardasil for the prevention of anal cancer and associated precancerous lesions due to human papillomavirus (HPV) types 6, 11, 16, and 18 in people ages 9 through 26 years. Gardasil already is approved for the same age population for the prevention of cervical, vulvar, and vaginal cancer and the associated precancerous lesions caused by HPV types 6, 11, 16, and 18 in females. It is also approved for the…

Continue

Added by Peter Hofland, PhD on December 22, 2010 at 1:30pm — No Comments

Research Shows Parent Favor Melanoma Genetic Testing for Their Children

Genetic testing of minors is controversial, as ethical considerations depend on multiple aspects of the particular disease and familial context. For melanoma, the most serious form of skin cancer, there is a well-established and avoidable environmental influence and a documented benefit of early detection. The vast majority of parents who tested positive for a genetic mutation that increases the risk of melanoma support genetic testing of their children or grandchildren. Results…

Continue

Added by Peter Hofland, PhD on December 21, 2010 at 7:00pm — No Comments

Rare Cancer Linked to Cell Oxygen Deficiency

Researchers at the National Institutes of Health have discovered that a rare cancer of the digestive tract is linked to a shutdown in an enzyme that helps supply oxygen to cells. In some cases, the enzyme's failure to function resulted from errors in genes containing the information needed to make the enzyme. In others, the cause could not be identified,…

Continue

Added by Peter Hofland, PhD on December 21, 2010 at 1:00pm — No Comments

NDA Submission (US) and European Marketing Application for Abiraterone Acetate in Metastatic Advanced Prostate Cancer

A New Drug Application (NDA) has been submitted by Centocor Ortho Biotech Inc to the U.S. Food and Drug Administration (FDA) for the investigational drug abiraterone acetate administered with prednisone for the treatment of metastatic advanced prostate cancer in patients who have received prior chemotherapy containing a taxane has been submitted At the same time Janssen-Cilag International NV filed a marketing authorization application (MAA) with the European Medicines Agency…

Continue

Added by Peter Hofland, PhD on December 20, 2010 at 3:30pm — No Comments

Intensive Chemotherapy May Dramatically Boost Survival of Older Teenage Leukemia Patients

Research led by St. Jude Children's Research Hospital investigators will likely impact how acute lymphoblastic leukemia is treated in young adults and shows older adolescent age does not dictate worse outcomes against the most common childhood cancer. More effective risk-adjusted chemotherapy and sophisticated patient monitoring helped push cure rates to nearly 88% for older adolescents enrolled in a St. Jude Children's…

Continue

Added by Peter Hofland, PhD on December 20, 2010 at 2:30pm — No Comments

Trial Starts for AC430, A Selective Janus Kinase 2 (JAK2) Inhibitor, and AC480, A Pan-HER Inhibitor

Earlier today, Ambit Biosciences (San Diego, USA) announced that it had started recruitment for two separate Phase I trials, the first one for AC430, a selective Janus Kinase 2 (JAK2) inhibitor, and the second for AC480 (also known as BMS-599626 ), a pan-HER inhibitor.



The Phase I trial for AC430 is a two part, placebo-controlled, single ascending, and multiple ascending dose trial in healthy…

Continue

Added by Peter Hofland, PhD on December 20, 2010 at 1:30pm — No Comments

COMFORT-I, a Pivotal Phase III Trial of INCB18424 in Myelofibrosis, Meets Primary and Key Secondary Endpoints

Top-line results from COMFORT-I, the pivotal Phase III clinical trial of INCB18424, also known as INC424, currently being developed by Incyte Corporation in patients with myelofibrosis (MF) being conducted under the U.S. Food and Drug Administration (FDA) Special Protocol Assessment (SPA) Agreement shows… Continue

Added by Peter Hofland, PhD on December 20, 2010 at 11:30am — No Comments

Phase I/II Trial of PI-3 Kinase Inhibitor PX-866 in Combination with Cetuximab for the Treatment of CRC or SCCHN Starts Recruiting Participants

Enrollment of the first patient in a Phase I/II trial of PX-866 in combination with the chimeric monoclonal antibody cetuximab (Erbitux®, ImClone LLC/Bristol-Myers Squibb Company) started today. PX-866 is a small molecule compound designed to inhibit the activity of phosphatidylinositol-3-kinase (PI-3K), a component of an important cell survival signaling pathway is activated in many types of human cancer. Aberrant activation…

Continue

Added by Peter Hofland, PhD on December 20, 2010 at 8:00am — No Comments

Committee for Medicinal Products for Human Use Issues Positive Opinion for Teysuno™ as First-Line Therapy for Advanced Gastric Cancer

The Committee for Medicinal Products for Human Use (CHMP), a division of the European Medicines Agency (EMA), has issued a positive opinion recommending approval of Teysuno™ (S-1), a novel oral anti-cancer agent, intended for the treatment of advanced gastric cancer in adults when given in combination with cisplatin.



With an estimated 934,000 new cases per year (8.6% of all new cancer cases), gastric cancer is the fourth most common cancer worldwide,…

Continue

Added by Peter Hofland, PhD on December 17, 2010 at 9:30am — No Comments

European Medicines Agency's Review of Bevacizumab in Metastatic Breast Cancer Contradicts US FDA Assessment

Bevacizumab (Avastin®, Genentech/Roche) in combination with paclitaxel remains a treatment option for women with breast cancer, but not with other combinations. Earlier today the European Medicines Agency (EMA) confirmed that the benefits of bevacizumab in combination with paclitaxel outweigh its risks and that this combination remains a valuable treatment option for patients suffering from metastatic breast cancer.



The decision by the European regulators…

Continue

Added by Peter Hofland, PhD on December 16, 2010 at 10:00am — No Comments

Process To Remove Breast Cancer Indication - Bevacizumab Not Shown To Be Safe and Effective In Breast Cancer Patients

The U.S. Food and Drug Administration (FDA) announced today that the agency is recommending removing the breast cancer indication from the label for bevacizumab (Avastin®, Genentech/Roche) because the drug has not been shown to be safe and effective for that use.



The FDA is making this recommendation after reviewing the results of four clinical studies of bevacizumab in women with HER2-negative, metastatic…

Continue

Added by Peter Hofland, PhD on December 16, 2010 at 9:30am — No Comments

Comprehensive Study of Medulloblastoma Suggests Targeted Drugs May Be Especially Effective in Children

Pediatric cancer researchers at The Children's Hospital of Philadelphia contributed important expertise to a new landmark study of medulloblastoma, a type of brain tumor typically found in children. The large multicenter study defines the genetic landscape of this cancer, and holds intriguing clues to gene changes on signaling pathways that may become fruitful targets for future therapies.



The most common…

Continue

Added by Peter Hofland, PhD on December 16, 2010 at 9:30am — No Comments

New Study Investigates Single-Dose Radiation Treatment for Prostate Cancer

Radiation oncologists have launched a new research study to treat men with low to intermediate risk prostate cancer with a single dose of radiation. Alvaro Martinez, M.D., FACR, professor and chair, Oakland University William Beaumont School of Medicine, department of Radiation Oncology, Beaumont Hospitals , performed the first-in-the-world one-dose, High-Dose Rate brachytherapy procedure Nov. 29 on a man from…

Continue

Added by Peter Hofland, PhD on December 16, 2010 at 9:00am — No Comments

Improvements in Recurrence-Free Survival in Early Stages of Colorectal Cancer Will Limit Growth of Drug Treatment Opportunities for Advanced Disease

Projected improvements in recurrence-free survival in early stages of colorectal cancer is the most important factor limiting drug treatment opportunities for advanced disease.According to analysis of Pharmacor Patient Flow Model Colorectal Cancer, the growth in drug treatment opportunities for advanced disease will be limited to 15% between 2009 and 2024.



"Drug treatment opportunities for advanced colorectal cancer will be limited because of a sustained…

Continue

Added by Peter Hofland, PhD on December 16, 2010 at 6:30am — No Comments

New Genetic Markers Improve the Power of PSA Testing for Detecting Prostate Cancer

Scientists from deCODE genetics and academic colleagues from Iceland, the UK, US, Netherlands, Spain and Romania today report the discovery of a set of single-letter variations in the sequence of the human genome (SNPs) that impact individual baseline levels of prostate specific antigen, or PSA. Testing for PSA levels is the most commonly used screening tool for the detection of prostate cancer. A prostate biopsy is routinely…

Continue

Added by Peter Hofland, PhD on December 15, 2010 at 11:30pm — No Comments

Clinical Trial to Evaluate Intravenous JX-594 in Patients With Refractory Metastatic Colorectal Cancer Starts in Korea

San Francisco based Jennerex, Inc., a private clinical-stage biotherapeutics company and Transgene , a member of the Institut Merieux Group initiated the enrollment and treatment of patients in a Phase 1b clinical trial to evaluate JX-594 (Vaccinia GM-CSF/thymidine kinase-deactivated virus…

Continue

Added by Peter Hofland, PhD on December 15, 2010 at 11:30pm — No Comments

Early Research Suggests That The Immune System Can Affect Angiogenesis.

Scientists at the Dana-Farber Cancer Institute may have uncovered a mechanism for blocking tumor angiogenesis that involves the patient’s immune system, according to findings published in Cancer Research, a journal of the American Association for Cancer Research.



Angiogenesis is the process by which tumors acquire and process blood, which is needed for their continued growth. Anti-angiogenesis drugs block blood flow and are an important part of cancer…

Continue

Added by Peter Hofland, PhD on December 15, 2010 at 4:00pm — No Comments

First Independent Validation Study of Colon Cancer Recurrence Test Shows Significant Improvement In Prognostic Accuracy

The colon cancer recurrence test ColoPrint® (Agendia, Amsterdam, The Netherlands) significantly improves prognostic accuracy over assessment solely based on pathologic factors and microsatellite instability in patients with stage II and III colorectal cancer who are either at low risk or at high risk of experiencing a disease relapse. In combination with classical pathological criteria, ColoPrint facilitates the identification of stage II patients who may be safely managed without… Continue

Added by Peter Hofland, PhD on December 15, 2010 at 4:30am — No Comments

Monthly Archives

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2005

2004

2001

Register for free to view all the Onco'Zine - The International Oncology Network content:

ADVERTISEMENT/MEDIA PARTNER

Onco'Zine is present here

Bookmark / Share

CONNECT WITH US AND

JOIN THE CONVERSATION


© 2017   Created by Peter Hofland, PhD.   Powered by

Badges  |  Report an Issue  |  Terms of Service

Find us on Google+